

# Elisabetta Bugianesi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2635016/publications.pdf>

Version: 2024-02-01

147  
papers

23,301  
citations

21215

62  
h-index

10129

145  
g-index

152  
all docs

152  
docs citations

152  
times ranked

21945  
citing authors

#	ARTICLE	IF	CITATIONS
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	6.1	113
2	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
3	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
4	Hepatocyte-Specific Deletion of HIF2 $\beta$ Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 459-482.	2.3	13
5	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	2.4	35
6	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
7	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	6.3	257
8	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 53-60.	1.0	4
9	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 635.	1.0	12
10	Oncostatin $\alpha$ is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. <i>Journal of Pathology</i> , 2022, 257, 82-95.	2.1	12
11	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	1.8	54
12	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. <i>Biomedicines</i> , 2022, 10, 792.	1.4	4
13	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	1.9	4
14	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	3.6	31
15	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 596-606.	1.8	38
16	An international survey on patterns of practice in NAFLD and expectations for therapiesâ€“The POPâ€“NEXT project. <i>Hepatology</i> , 2022, 76, 1766-1777.	3.6	7
17	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135
18	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	2.6	31

#	ARTICLE	IF	CITATIONS
19	A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers. <i>Panminerva Medica</i> , 2022, 64, .	0.2	5
20	NAFLD/NASH. <i>Journal of Hepatology</i> , 2022, 77, 549-550.	1.8	10
21	Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 638-651.	8.2	69
22	Current therapies and new developments in NASH. <i>Gut</i> , 2022, 71, 2123-2134.	6.1	82
23	Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2022, 25, 285-291.	1.3	5
24	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	2.4	90
25	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	1.8	193
26	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	1.3	4
27	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021, 11, 155.	1.3	44
28	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
29	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101611.	0.7	0
30	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	1.9	76
31	Inflammatory Bowel Disease Nurseâ€™ Practical Messages. <i>Nursing Reports</i> , 2021, 11, 229-241.	0.8	8
32	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	1.7	24
33	Natural history of NASH. <i>Liver International</i> , 2021, 41, 78-82.	1.9	16
34	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohnâ€™s Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3387.	1.0	16
35	Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2021, 41, 1999-2008.	1.9	7
36	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3257.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	2.7	11
38	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	1.4	9
39	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	0.6	229
40	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	1.8	100
41	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021, 372, m4747.	3.0	99
42	Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4961.	1.0	8
43	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 716533.	1.5	27
44	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	3.6	209
45	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	3.6	66
46	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. <i>Cells</i> , 2020, 9, 28.	1.8	26
47	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2776.	1.7	14
48	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	0.8	71
49	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
50	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	1.8	22
51	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020, 9, 2353.	1.0	18
52	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1289-1292.	0.2	9
53	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	1.2	2
54	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3941.	1.0	34

#	ARTICLE	IF	CITATIONS
55	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	1.7	27
56	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1323.	1.0	20
57	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2489-2499.	1.9	9
58	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 800.	1.0	29
59	Fatty liver disease: putting the spotlight on a silent menace for young adults. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 236-238.	3.7	9
60	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114985.	0.8	14
61	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
62	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	1.8	279
63	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	1.1	3
64	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
65	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	1.8	128
66	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1646.	1.0	50
67	The next decade of metabolism. <i>Nature Metabolism</i> , 2019, 1, 2-4.	5.1	8
68	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019, 19, 56.	0.8	65
69	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 3682.	1.6	85
70	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	2.4	66
71	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- $\beta$ 1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	1.6	7
72	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107

#	ARTICLE	IF	CITATIONS
73	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6333.	1.8	24
74	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
75	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.2	57
76	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	3.6	1,203
77	A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 80-82.	8.2	29
78	NASH in Lean Individuals. <i>Seminars in Liver Disease</i> , 2019, 39, 086-095.	1.8	161
79	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	1.8	67
80	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019, 110, 401-409.	0.3	22
81	Hypoxia-inducible factor 2 $\alpha$ drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. <i>Hepatology</i> , 2018, 67, 2196-2214.	3.6	66
82	Reply to "Definition of Small for Gestational Age and Low Birthweight". <i>American Journal of Gastroenterology</i> , 2018, 113, 442.	0.2	0
83	Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>Journal of Medical Virology</i> , 2018, 90, 320-327.	2.5	80
84	Usefulness of the index of <sc>NASH</sc> " <sc>ION</sc> for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018, 38, 715-723.	1.9	22
85	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 11-20.	8.2	3,487
86	Reply. <i>Hepatology</i> , 2018, 67, 1178-1180.	3.6	0
87	Should we undertake surveillance for HCC in patients with NAFLD?. <i>Journal of Hepatology</i> , 2018, 68, 326-334.	1.8	145
88	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018, 67, 145-158.	3.6	296
89	The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. <i>Current Hepatology Reports</i> , 2018, 17, 336-344.	0.4	2
90	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018, 69, 1155-1163.	1.8	80

#	ARTICLE	IF	CITATIONS
91	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	1.8	113
92	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017, 37, 1389-1396.	1.9	44
93	IFN- $\gamma$ 3, not IFN- $\gamma$ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	9.4	86
94	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1277-1286.	0.2	38
95	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	1.3	43
96	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , 2017, 60, 1873-1882.	2.9	85
97	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	1.6	193
98	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR- $\gamma$ agonists. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 64-68.	1.5	17
99	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524
100	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0172575.	1.1	49
101	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	1.8	126
102	Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. <i>International Journal of Molecular Sciences</i> , 2016, 17, 479.	1.8	70
103	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. <i>International Journal of Molecular Sciences</i> , 2016, 17, 717.	1.8	158
104	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0163069.	1.1	63
105	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	3.6	67
106	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2016, 48, 55-61.	0.4	19
107	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?. <i>Diabetologia</i> , 2016, 59, 1145-1147.	2.9	15
108	Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs". <i>Digestive and Liver Disease</i> , 2016, 48, 1101-1102.	0.4	0



#	ARTICLE	IF	CITATIONS
109	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. <i>Liver International</i> , 2016, 36, 1563-1579.	1.9	126
110	Childhood obesity: time bomb for future burden of chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 506-507.	8.2	4
111	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.	5.8	104
112	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	1.6	33
113	The macrophage activation marker $\alpha$ CD163 is associated with morphological disease stages in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1549-1557.	1.9	94
114	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	3.6	83
115	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	1.8	64
116	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 682-690.	1.8	106
117	Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. <i>Digestive and Liver Disease</i> , 2016, 48, 105-111.	0.4	54
118	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.4	56
119	Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. <i>Clinics in Liver Disease</i> , 2016, 20, 313-324.	1.0	120
120	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. <i>Annual Review of Medicine</i> , 2016, 67, 103-117.	5.0	535
121	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15080.	18.1	612
122	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. <i>Digestive and Liver Disease</i> , 2015, 47, 405-410.	0.4	9
123	Interferon- $\gamma$ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.	5.8	156
124	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. <i>Seminars in Liver Disease</i> , 2015, 35, 236-249.	1.8	66
125	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1037-46.	1.2	52
126	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 1566-1573.	1.9	116



#	ARTICLE	IF	CITATIONS
127	Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 109-116.	0.7	96
128	Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1163-1169.e1.	2.4	41
129	NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really?. <i>Current Hepatology Reports</i> , 2014, 13, 113-118.	0.4	4
130	379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2014, 146, S-909.	0.6	94
131	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	1.1	112
132	Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. <i>Nutrients</i> , 2013, 5, 1544-1560.	1.7	648
133	Hepatic and Cardiac Steatosis. <i>Heart Failure Clinics</i> , 2012, 8, 663-670.	1.0	19
134	Reliability of transient elastography for the detection of fibrosis in Non-Alcoholic Fatty Liver Disease and chronic viral hepatitis. <i>Journal of Hepatology</i> , 2011, 54, 64-71.	1.8	230
135	Complex noninvasive fibrosis models are more accurate than simple models in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1536-1543.	1.4	145
136	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011, 48, 337-343.	1.2	22
137	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 697-706.	3.6	140
138	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. <i>Current Diabetes Reports</i> , 2007, 7, 175-180.	1.7	56
139	Reply:. <i>Hepatology</i> , 2006, 43, 1168-1169.	3.6	18
140	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <i>Hepatology</i> , 2006, 44, 1648-1655.	3.6	137
141	Insulin resistance: A metabolic pathway to chronic liver disease. <i>Hepatology</i> , 2005, 42, 987-1000.	3.6	730
142	Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3498-3504.	1.8	370
143	A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 1082-1090.	0.2	631
144	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , 2004, 39, 179-187.	3.6	394

#	ARTICLE	IF	CITATIONS
145	Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2004, 39, 1749-1749.	3.6	7
146	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 1105-1116.	1.0	32
147	Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. <i>Gastroenterology</i> , 2002, 123, 134-140.	0.6	1,332